Intellicyt has developed a novel solution to disrupt the traditional antibody discovery workflow. Success of antibody-based block-buster therapeutics for autoimmune diseases, inflammatory diseases and immune-oncology have accelerated high stakes monoclonal antibody (mAb) discovery—a time-consuming process in which therapeutic antibody candidates are initially generated using hybridoma technology or primary B cell screening after antigen immunization. The primary screens identify clones with specific attributes (binding specificity, cross species reactivity, selectivity and affinity). Potential candidates from the screen are then assessed for a variety of critical parameters for lead molecule generation such as IgG isotyping, antibody quantification, and cell number/health. This process typically involves single-endpoint assays requiring sample dilution and multiple washes.
That all changes with the Intellicyt Mouse IgG Type and Titer Kit, a patented high throughput, multiplexed assay with a wide dynamic range requiring no sample dilution or wash steps. The simple mix-and-read workflow simultaneously measures five endpoints:
The Mouse IgG Type and Titer assay is part of Intellicyt’s integrated antibody discovery platform technology. The iQue Screener PLUS can acquire data in as little as 20 minutes per 384-well plate, while ForeCyt software provides powerful data mining tools for large hybridoma/B-cell screening studies. ForeCyt’s Panorama feature provides interactive and visual multi-plate data analysis including profile maps with user-specified criteria to quickly identify samples containing the desired IgG isotype, antibody concentration and cell health, critical for analyzing data from large, multi-plate screening campaigns. The total time from samples to actionable data is less than 100 minutes.